PMID- 36127675
OWN - NLM
STAT- MEDLINE
DCOM- 20220923
LR  - 20231103
IS  - 1471-2415 (Electronic)
IS  - 1471-2415 (Linking)
VI  - 22
IP  - 1
DP  - 2022 Sep 20
TI  - Retinal changes of primary vitreoretinal lymphoma after intravitreal 
      methotrexate.
PG  - 375
LID - 10.1186/s12886-022-02604-7 [doi]
LID - 375
AB  - BACKGROUND: To identify retinal changes using spectral-domain optical coherence 
      tomography (SD-OCT) and ultra-widefield images in eyes with primary vitreoretinal 
      lymphoma (PVRL) during intravitreal methotrexate (MTX) treatment.  METHODS: This 
      study retrospectively reviewed 111 eyes of 58 patients with vitreous 
      cytology-proven confirmed PVRL, who received intravitreal injections of MTX. 
      RESULTS: At the initial visit, the OCT manifestations included vitreous cells 
      (105 eyes, 94.6%), intraretinal infiltration (44 eyes,39.6%), subretinal 
      infiltration (45 eyes, 40.5%,), retinal pigment epithelium (RPE) abnormalities 
      (66 eyes, 59.5%), disruption of the ellipsoid zone (58 eyes, 52.3%), subretinal 
      fluid (4 eyes, 3.6%), RPE detachment (PED) (28 eyes, 25.2%), epiretinal membrane 
      (ERM) (8 eyes, 7.2%), macular edema (10 eyes, 9%). After therapy, tumor 
      regression was achieved in all eyes. Between the initial presentation and 
      regression, the vitreous cells (94.6% vs. 0%, P < 0.001), intraretinal 
      infiltration (39.6% vs. 0%, P < 0.001), RPE abnormalities (59.5% vs.19.8%, 
      P < 0.001), PED (25.2% vs.0%, P < 0.001), and subretinal infiltration 
      (40.5%vs.16.2%, P < 0.001) were significantly reduced. The fundus photography 
      findings all improved after therapy. The mean Logarithm of the Minimum Angle of 
      Resolution (logMAR) for the best corrected visual acuity (BCVA) at presentation 
      was 0.79 +/- 0.81 (range, 0-2.9), which improved to 0.70 +/- 0.97 (range, 0-2.9, 
      P = 0.01) at the final visit. CONCLUSIONS: SD-OCT combined with ultra-widefield 
      imaging, which can reflect retinal changes, are valuable tools for monitoring the 
      effect of PVRL treatment.
CI  - (c) 2022. The Author(s).
FAU - Jiang, Tingting
AU  - Jiang T
AD  - Department of Ophthalmology, Eye and ENT Hospital, Fudan University, 83 Fenyang 
      Road, Shanghai, 200031, China.
AD  - Shanghai Key Laboratory of Visual Impairment and Restoration, Shanghai, 200031, 
      China.
AD  - Key Laboratory of Myopia of National Health Commission, Fudan University, 
      Shanghai, 200031, China.
AD  - Key Laboratory of Myopia, Chinese Academy of Medical Sciences, Shanghai, 200031, 
      China.
FAU - Gu, Junxiang
AU  - Gu J
AD  - Department of Ophthalmology, Eye and ENT Hospital, Fudan University, 83 Fenyang 
      Road, Shanghai, 200031, China.
AD  - Shanghai Key Laboratory of Visual Impairment and Restoration, Shanghai, 200031, 
      China.
AD  - Key Laboratory of Myopia of National Health Commission, Fudan University, 
      Shanghai, 200031, China.
AD  - Key Laboratory of Myopia, Chinese Academy of Medical Sciences, Shanghai, 200031, 
      China.
FAU - Liu, Shixue
AU  - Liu S
AD  - Department of Ophthalmology, Eye and ENT Hospital, Fudan University, 83 Fenyang 
      Road, Shanghai, 200031, China.
AD  - Shanghai Key Laboratory of Visual Impairment and Restoration, Shanghai, 200031, 
      China.
AD  - Key Laboratory of Myopia of National Health Commission, Fudan University, 
      Shanghai, 200031, China.
AD  - Key Laboratory of Myopia, Chinese Academy of Medical Sciences, Shanghai, 200031, 
      China.
FAU - Chang, Qing
AU  - Chang Q
AD  - Department of Ophthalmology, Eye and ENT Hospital, Fudan University, 83 Fenyang 
      Road, Shanghai, 200031, China. qngchang@aliyun.com.
AD  - Shanghai Key Laboratory of Visual Impairment and Restoration, Shanghai, 200031, 
      China. qngchang@aliyun.com.
AD  - Key Laboratory of Myopia of National Health Commission, Fudan University, 
      Shanghai, 200031, China. qngchang@aliyun.com.
AD  - Key Laboratory of Myopia, Chinese Academy of Medical Sciences, Shanghai, 200031, 
      China. qngchang@aliyun.com.
LA  - eng
GR  - 81500734/National Natural Science Foundation of China/
GR  - 81870670/National Natural Science Foundation of China/
GR  - 18411965100/Shanghai Science and Technology Commission project/
GR  - SHDC2020CR5014-003/Shanghai Shenkang Hospital Development Center Project/
PT  - Journal Article
DEP - 20220920
PL  - England
TA  - BMC Ophthalmol
JT  - BMC ophthalmology
JID - 100967802
RN  - YL5FZ2Y5U1 (Methotrexate)
SB  - IM
MH  - Fluorescein Angiography/methods
MH  - Humans
MH  - *Lymphoma/drug therapy/pathology
MH  - Methotrexate/therapeutic use
MH  - *Retinal Neoplasms/diagnosis/drug therapy/pathology
MH  - Retrospective Studies
MH  - Visual Acuity
MH  - Vitreous Body/pathology
PMC - PMC9487031
OTO - NOTNLM
OT  - Intravitreal chemotherapy
OT  - Methotrexate
OT  - Optical coherence tomography
OT  - Primary vitreoretinal lymphoma
COIS- The authors declare that they have no competing interests.
EDAT- 2022/09/21 06:00
MHDA- 2022/09/24 06:00
PMCR- 2022/09/20
CRDT- 2022/09/20 23:38
PHST- 2022/03/18 00:00 [received]
PHST- 2022/09/12 00:00 [accepted]
PHST- 2022/09/20 23:38 [entrez]
PHST- 2022/09/21 06:00 [pubmed]
PHST- 2022/09/24 06:00 [medline]
PHST- 2022/09/20 00:00 [pmc-release]
AID - 10.1186/s12886-022-02604-7 [pii]
AID - 2604 [pii]
AID - 10.1186/s12886-022-02604-7 [doi]
PST - epublish
SO  - BMC Ophthalmol. 2022 Sep 20;22(1):375. doi: 10.1186/s12886-022-02604-7.